386 related articles for article (PubMed ID: 15570081)
1. Short-term efficacy of methylphenidate: a randomized, double-blind, placebo-controlled trial among survivors of childhood cancer.
Mulhern RK; Khan RB; Kaplan S; Helton S; Christensen R; Bonner M; Brown R; Xiong X; Wu S; Gururangan S; Reddick WE
J Clin Oncol; 2004 Dec; 22(23):4795-803. PubMed ID: 15570081
[TBL] [Abstract][Full Text] [Related]
2. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder.
Wigal S; Swanson JM; Feifel D; Sangal RB; Elia J; Casat CD; Zeldis JB; Conners CK
J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1406-14. PubMed ID: 15502600
[TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
Biederman J; Melmed RD; Patel A; McBurnett K; Konow J; Lyne A; Scherer N;
Pediatrics; 2008 Jan; 121(1):e73-84. PubMed ID: 18166547
[TBL] [Abstract][Full Text] [Related]
4. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.
Research Units on Pediatric Psychopharmacology Autism Network
Arch Gen Psychiatry; 2005 Nov; 62(11):1266-74. PubMed ID: 16275814
[TBL] [Abstract][Full Text] [Related]
5. Modafinil improves symptoms of attention-deficit/hyperactivity disorder across subtypes in children and adolescents.
Biederman J; Pliszka SR
J Pediatr; 2008 Mar; 152(3):394-9. PubMed ID: 18280848
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
7. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
Medori R; Ramos-Quiroga JA; Casas M; Kooij JJ; Niemelä A; Trott GE; Lee E; Buitelaar JK
Biol Psychiatry; 2008 May; 63(10):981-9. PubMed ID: 18206857
[TBL] [Abstract][Full Text] [Related]
8. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder.
Fallu A; Richard C; Prinzo R; Binder C
Curr Med Res Opin; 2006 Dec; 22(12):2557-66. PubMed ID: 17166338
[TBL] [Abstract][Full Text] [Related]
9. Methylphenidate dosing: twice daily versus three times daily.
Stein MA; Blondis TA; Schnitzler ER; O'Brien T; Fishkin J; Blackwell B; Szumowski E; Roizen NJ
Pediatrics; 1996 Oct; 98(4 Pt 1):748-56. PubMed ID: 8885956
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of theophylline compared to methylphenidate for the treatment of attention-deficit hyperactivity disorder in children and adolescents: a pilot double-blind randomized trial.
Mohammadi MR; Kashani L; Akhondzadeh S; Izadian ES; Ohadinia S
J Clin Pharm Ther; 2004 Apr; 29(2):139-44. PubMed ID: 15068402
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study.
Spencer TJ; Abikoff HB; Connor DF; Biederman J; Pliszka SR; Boellner S; Read SC; Pratt R
Clin Ther; 2006 Mar; 28(3):402-18. PubMed ID: 16750455
[TBL] [Abstract][Full Text] [Related]
12. Factor analysis and validity of the Conners Parent and Teacher Rating Scales in childhood cancer survivors.
Helton SC; Corwyn RF; Bonner MJ; Brown RT; Mulhern RK
J Pediatr Psychol; 2006 Mar; 31(2):200-8. PubMed ID: 16467320
[TBL] [Abstract][Full Text] [Related]
13. Effects of methylphenidate treatment in children with mental retardation and ADHD: individual variation in medication response.
Pearson DA; Lane DM; Santos CW; Casat CD; Jerger SW; Loveland KA; Faria LP; Mansour R; Henderson JA; Payne CD; Roache JD; Lachar D; Cleveland LA
J Am Acad Child Adolesc Psychiatry; 2004 Jun; 43(6):686-98. PubMed ID: 15167085
[TBL] [Abstract][Full Text] [Related]
14. The neuropsychological effects of chronic methylphenidate on drug-naive boys with attention-deficit/hyperactivity disorder.
Coghill DR; Rhodes SM; Matthews K
Biol Psychiatry; 2007 Nov; 62(9):954-62. PubMed ID: 17543895
[TBL] [Abstract][Full Text] [Related]
15. The effect of methylphenidate on the cognitive and personality functioning of ADHD children.
Lufi D; Parish-Plass J; Gai E
Isr J Psychiatry Relat Sci; 1997; 34(3):200-9. PubMed ID: 9334525
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data.
Sonuga-Barke EJ; Swanson JM; Coghill D; DeCory HH; Hatch SJ
BMC Psychiatry; 2004 Sep; 4():28. PubMed ID: 15458569
[TBL] [Abstract][Full Text] [Related]
17. Acute neurocognitive response to methylphenidate among survivors of childhood cancer: a randomized, double-blind, cross-over trial.
Conklin HM; Khan RB; Reddick WE; Helton S; Brown R; Howard SC; Bonner M; Christensen R; Wu S; Xiong X; Mulhern RK
J Pediatr Psychol; 2007 Oct; 32(9):1127-39. PubMed ID: 17569711
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
[TBL] [Abstract][Full Text] [Related]
19. Immediate neurocognitive effects of methylphenidate on learning-impaired survivors of childhood cancer.
Thompson SJ; Leigh L; Christensen R; Xiong X; Kun LE; Heideman RL; Reddick WE; Gajjar A; Merchant T; Pui CH; Hudson MM; Mulhern RK
J Clin Oncol; 2001 Mar; 19(6):1802-8. PubMed ID: 11251012
[TBL] [Abstract][Full Text] [Related]
20. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
Biederman J; Mick E; Surman C; Doyle R; Hammerness P; Harpold T; Dunkel S; Dougherty M; Aleardi M; Spencer T
Biol Psychiatry; 2006 May; 59(9):829-35. PubMed ID: 16373066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
